Drugs / D46cpΔM2-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02601612 | Oct 2015 → Apr 2018 | respiratory syncytial virus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D46cpΔM2-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02601612 ↗ |
| Modality | Vaccine | “D46cpΔM2-2 vaccine” NCT02601612 ↗ |
| Route | Intranasal | “Delivered as nose drops” NCT02601612 ↗ |